Key Highlights
- Hemogenyx rose 7.54% to 727p on low absolute volume, with no fresh same-day announcement confirming a new clinical catalyst.
- The company dosed the first three HG-CT-1 patients, gained clearance for dose escalation and a paediatric arm, and completed manufacturing technology transfer.
- It had £1.6 million of cash at December 2025 and subsequently raised about £5.6 million, illustrating both improved runway and ongoing dilution risk.
Hemogenyx Pharmaceuticals plc (LSE: HEMO) rose 7.54% to 727p on the latest UK gainers screen. Trading volume was small in absolute terms, and there was no fresh same-day regulatory update identifying a new clinical result. The move may therefore reflect renewed interest in the HG-CT-1 trial, post-year funding and speculative positioning rather than a confirmed scientific breakthrough.
For an early-stage biotechnology company, a genuine breakout should be tested through clinical data, not a chart. Hemogenyx has passed important safety and manufacturing milestones, but it has no commercial revenue and remains exposed to trial failure, regulatory delay and future capital needs.
Company Overview
Hemogenyx develops therapies for blood cancers, autoimmune disease and related conditions. Its lead programme, HG-CT-1, is a chimeric antigen receptor T-cell therapy being studied in relapsed or refractory acute myeloid leukaemia. The broader pipeline includes CDX bispecific antibodies and a chimeric bait receptor platform.
The business model is to advance assets through clinical proof of concept and then potentially continue development, license programmes or form partnerships. That model can create substantial value if early data are compelling, but it requires years of research spending before dependable revenue.
Why The Shares Are Attracting Attention
During 2025, the first three adult patients received HG-CT-1 at the initial dose. An independent Data Safety Monitoring Board authorised escalation to the second dose level and allowed paediatric enrolment at the starting dose. The company also transferred manufacturing to Made Scientific, giving it external clinical-supply capacity.
Those steps move the programme from first-in-human initiation towards more informative dosing. The company raised additional equity in early 2026, reducing the immediate risk that the trial would stop for lack of cash. However, the latest 7.54% price move was not tied to new efficacy data, so technical and liquidity effects may have contributed.
Latest Financial Performance
Hemogenyx is pre-revenue, so its accounts primarily measure research spending and funding. For the year ended 31 December 2025, the group reported a loss of £9.77 million compared with £5.63 million. Operating expenditure increased as the Phase 1 trial, manufacturing transfer and regulatory work progressed. A £2.29 million fair-value loss on derivative instruments also affected the result.
Cash used in operations was £5.82 million, up from £4.14 million. The reported loss per share was 1.706p under the company's presentation. These figures do not indicate commercial performance; they indicate the cost and dilution involved in reaching clinical milestones.
Operational Performance
The first dose cohort established an initial safety foundation, with three adult patients treated. Clearance to escalate is important because higher doses may provide more meaningful evidence of biological activity. Paediatric expansion broadens the programme but adds recruitment, ethical and operational complexity.
Technology transfer to Made Scientific was completed and a comparability package was submitted to the US Food and Drug Administration. External manufacturing can reduce fixed costs and provide specialist capacity, although quality, scheduling and supply-chain oversight remain the sponsor's responsibility. The company filed its annual investigational-new-drug report and continues to operate the study under FDA supervision.
Balance Sheet, Cash Flow And Funding
Group cash was £1.59 million at 31 December 2025, compared with £0.16 million a year earlier. During the year, equity and related instruments provided funding, and the company subsequently raised £2.5 million, received £0.12 million from warrant exercise and completed a £3.0 million direct subscription.
Management stated that the post-year raises were expected to finance completion of the current Phase 1 programme on envisaged timelines. That improves visibility but does not eliminate future funding needs for later-stage trials, manufacturing or other pipeline assets. Each equity issue increases the share count and can dilute existing holders.
Recent Announcements And Strategic Developments
The Made Scientific transfer is a key operational de-risking step because it establishes a GMP-capable external manufacturing route for clinical supply. Hemogenyx also signed a non-binding letter of intent with Estonia-based Cellin Technologies to explore early commercialisation through a hospital-exemption pathway.
Hospital exemption would not replace full marketing authorisation, and the arrangement is not yet a definitive commercial agreement. It offers optionality and possible real-world data, but investors should not treat it as contracted revenue. The April institutional subscription provided £3 million at a reported issue price of £8.01 per share.
Industry And Economic Backdrop
CAR-T therapies have transformed some blood-cancer treatments, but acute myeloid leukaemia remains a difficult target. Manufacturing is personalised, patients are seriously ill and early trials are small. Safety signals, response durability and dose selection are therefore critical.
Small biotechnology companies also face challenging capital markets. Higher interest rates and risk aversion can make equity expensive, particularly before proof of concept. Partnerships can provide capital and expertise, but negotiating leverage generally improves only after robust clinical data.
Potential Growth Drivers
The strongest value driver would be clear safety and efficacy at higher HG-CT-1 doses. Successful paediatric enrolment could broaden the addressable population, while reliable manufacturing would support expansion. A definitive Cellin agreement could create an early access route, subject to regulation and clinical suitability.
The CDX and CBR platforms provide additional optionality, although resources are limited and HG-CT-1 is the main near-term focus. Strategic partnerships, grants or licensing could reduce the amount of shareholder-funded development if counterparties are willing to commit capital.
Upcoming Milestones Or Catalysts
Investors should watch for dosing at the second adult dose level, paediatric recruitment, safety reviews and any preliminary response data. Regulatory feedback on the manufacturing comparability package is also important. A definitive agreement with Cellin would be more meaningful than the existing letter of intent.
Updates on cash use and trial timing will shape funding expectations. Because patient recruitment and manufacturing can shift, management should provide clear dates and explain delays rather than relying on broad development language.
Principal Risks And Uncertainties
HG-CT-1 may fail because of toxicity, limited efficacy, manufacturing problems or recruitment delays. Early observations from three patients cannot establish effectiveness. Regulators can request more data or pause a study. Intellectual-property protection and competition from better-funded developers are also material.
The company has no recurring revenue and depends on external capital. Future rounds may be dilutive or unavailable. A small free float and limited trading can produce large price swings. Letters of intent and early clinical signals should not be valued as completed commercial outcomes.
Investment Perspective
Hemogenyx made genuine progress by dosing its first cohort, obtaining escalation clearance and completing technology transfer. Post-year funding gives the team a better chance to execute the next stage. These are credible reasons for investor interest.
The evidence remains preliminary. The programme has not yet demonstrated repeatable clinical efficacy, and later development will require more capital. Patient recruitment and manufacturing consistency will also remain essential. The stock can move higher on strong data, but the same clinical and financing leverage can work in reverse.
Outlook
HemoGenyx Pharmaceuticals (LSE: HEMO) is preparing for a more informative phase of HG-CT-1 development, not an assured market breakout. The 7.54% jump appears to reflect renewed attention rather than a fresh result. Higher-dose data, paediatric progress and funding discipline will determine whether the clinical story earns a sustained re-rating.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...